Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma

Cancer, 04/16/2012

Giglio P et al. – The combination of thalidomide and irinotecan did not achieve sufficient efficacy to warrant further investigation against anaplastic gliomas (AGs), although a subset of patients experienced prolonged progression–free survival (PFS)/overall survival (OS). A trial of the more potent thalidomide analogue, lenalidomide, in combination with irinotecan against AG is currently ongoing.